Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Aveni Foundation
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Var2 Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Nationwide Children's Hospital
NextPoint Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
University Medical Center Groningen
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
BTG International Inc.
National Cancer Institute (NCI)
Children's National Research Institute
Eastern Cooperative Oncology Group
Florida International University
MacroGenics
Dana-Farber Cancer Institute
Barbara Ann Karmanos Cancer Institute
Emory University
Celgene
Emory University
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Nationwide Children's Hospital
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences